[Chemo-induced mucositis in pediatric oncology: Perspectives?]
Marilyne Poirée1, Cyril Lervat2, Perrine Marec-Berard3
1Hôpital Archet 2, service d'oncohématologie pédiatrique, route Saint-Antoine-de-Ginestière, 06202 Nice, France.
Bulletin Du Cancer
|May 2, 2021
Summary
Chemo-induced mucositis, an oral and gastrointestinal side effect of cancer treatment, significantly impacts patient quality of life. This study highlights varied management practices and proposes new guidelines for pediatric oral mucositis prevention and treatment.
Area of Science:
- Oncology
- Gastroenterology
- Pediatrics
Background:
- Mucositis, characterized by oral and gastrointestinal lesions, affects a significant portion of chemotherapy patients.
- It severely reduces quality of life, causing pain, infection risk, and treatment alterations.
- Current management strategies for mucositis are inconsistent and challenging.
Purpose of the Study:
- To assess current practices for managing chemotherapy-induced mucositis in French pediatric oncology.
- To identify variations in preventive and curative approaches.
- To propose evidence-based guidelines for oral mucositis in pediatric cancer patients.
Main Methods:
- A multicentric survey was conducted across French pediatric oncology departments.
- A standardized questionnaire assessed preventive and curative mucositis management practices.
- Recent literature on oral mucositis was analyzed.
Main Results:
- Survey results revealed heterogeneous practices in mucositis management.
- Limited progress in standardized care has been observed over the past decade.
- Practices for chemotherapy-induced oral mucositis in children vary widely.
Conclusions:
- There is a need for standardized guidelines for pediatric oral mucositis.
- The study proposes guidelines based on national survey data and literature review.
- Implementing consistent protocols can improve the management of this toxic side effect.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
415
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
415
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
322
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
322
02:49Cancer Therapies
8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
471
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
471
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
585
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
585
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
56
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
56